Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Merck
Novartis
US Department of Justice
Fish and Richardson
Medtronic
Fuji
Mallinckrodt
Argus Health
Johnson and Johnson

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,859,562

« Back to Dashboard

Which drugs does patent 8,859,562 protect, and when does it expire?


Patent 8,859,562 protects RUBRACA and LYNPARZA and is included in three NDAs.

This patent has fifty-two patent family members in twenty-three countries.

Summary for Patent: 8,859,562

Title:Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Abstract: The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.
Inventor(s): Helleday; Thomas (Stockholm, SE)
Assignee: The University of Sheffield (Sheffield, GB)
Application Number:10/555,507
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-001Dec 19, 2016RXYesNo► Subscribe► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-003May 1, 2017RXYesNo► Subscribe► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-002Dec 19, 2016RXYesYes► Subscribe► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
TABLET;ORAL208558-001Aug 17, 2017RXYesNo► Subscribe► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
TABLET;ORAL208558-002Aug 17, 2017RXYesYes► Subscribe► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
CAPSULE;ORAL206162-001Dec 19, 2014RXYesYes► Subscribe► Subscribe TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,859,562

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0317466.1Jul 25, 2003
PCT Information
PCT FiledJuly 23, 2004PCT Application Number:PCT/GB2004/003235
PCT Publication Date:February 10, 2005PCT Publication Number: WO2005/012524

Non-Orange Book Patents for Patent: 8,859,562

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,351,701Therapeutic compounds► Subscribe
7,531,530Therapeutic compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,859,562

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2533332► Subscribe
Canada2533423► Subscribe
China1856313► Subscribe
China1856572► Subscribe
China102935230► Subscribe
Denmark1649017► Subscribe
Cyprus1110335► Subscribe
Germany602004025123► Subscribe
Denmark1660095► Subscribe
European Patent Office1649017► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Julphar
Mallinckrodt
Citi
AstraZeneca
Medtronic
Fish and Richardson
Deloitte
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot